Chinese Journal of Cancer Research's 2026 Journal Metrics Score is 5.3, ranking Q1 in Pulmonary and Respiratory Medicine and 2 other subfields. Two-year citation average from OpenAlex data, updated August 2026.
Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.
Journal Metrics Score 2026 · 2021–2024 window citedness 5.66.
Middle 50%: 51–105 days
98 of 100 PubMed-indexed articles · 98% coverage · 2024–2025
No journal-level APC is available in the current OpenAlex snapshot. Cost is excluded from scoring.
Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.
Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.
Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.
63 of 235 works · same type, year & subfield
5 works · same type, year & subfield
Above field-year expectation
of 2,036 topic-associated OpenAlex sources by lifetime output
FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 1.20, so its typical recent paper runs about 20% above its field benchmark.
26.8% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.
Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.
OpenAlex source records · 2016–2025
235 OpenAlex works · 2021–2024
OpenAlex topics show the research communities this journal serves.
Candidates share at least one OpenAlex subfield (or field, if too few do) with this journal's main research topics, ignoring generic catch-all topics, and are ordered by topic overlap, then current Journal Metrics Score.
* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.
| Category | Quartile |
|---|---|
| Pulmonary and Respiratory Medicine | Q1 |
| Oncology | Q1 |
| Surgery | Q1 |
Yes. A Q1 journal by citation data
Yes. By citation data, Chinese Journal of Cancer Research is a strong journal: it is Q1 in Pulmonary and Respiratory Medicine and 2 other subfields and ranks #120 of 897 Oncology journals by Journal Metrics Score (top 14%). Chinese Journal of Cancer Research's 2026 Journal Metrics Score is 5.3. Recent papers took a median of 78 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Pulmonary and Respiratory Medicine, Oncology, and Surgery, so check that your topic fits its scope.
Verdict from citation data only: quartile and field rank by Journal Metrics Score (OpenAlex), publisher-reported acceptance rates, and PubMed submission and acceptance dates. See how we rank journals and how to verify indexing.
Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.
Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.
OpenAlex classifies Chinese Journal of Cancer Research's papers in subfields including Pulmonary and Respiratory Medicine, Oncology, and Surgery. Read the aims and scope page and a few recent papers close to your topic before you prepare the manuscript.
Article types, word and figure limits, reference style, and the required statements (data availability, ethics, conflicts of interest, author contributions) are set by the journal. Prepare the cover letter and files to match them.
Chinese Journal of Cancer Research homepage ↗Use the submit link in Chinese Journal of Cancer Research's author guidelines; AME Publishing Company runs the submission site. Every author usually needs an ORCID iD, and the corresponding author needs an account on the submission site.
The journal is fully open access, and OpenAlex has no article processing charge on record. Check the journal website for current fees and waivers.
Recent accepted papers took a median of 78 days from submission to acceptance, including revisions (PubMed dates). Chinese Journal of Cancer Research does not publish an acceptance rate.
New on PubMed
Type a topic to see the newest PubMed papers from the past week and the big picture of what they found, summarized by Claude on the Pro plan. Get a free weekly email to keep up.
See a demo:GLP-1CRISPRLong COVID
Reviewer Two · coming soon
An AI pre-submission report on your manuscript: the objections a tough reviewer is likely to raise, desk-rejection risks, and better-fit journals from our data. $29 per report.
See what the report coversYes. By citation data, Chinese Journal of Cancer Research is a strong journal: it is Q1 in Pulmonary and Respiratory Medicine and 2 other subfields and ranks #120 of 897 Oncology journals by Journal Metrics Score (top 14%). Chinese Journal of Cancer Research's 2026 Journal Metrics Score is 5.3. Recent papers took a median of 78 days from submission to acceptance, according to PubMed dates. OpenAlex classifies its papers in subfields including Pulmonary and Respiratory Medicine, Oncology, and Surgery, so check that your topic fits its scope.
Chinese Journal of Cancer Research's 2026 Journal Metrics Score is 5.3, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.
We have not found an official acceptance rate published by Chinese Journal of Cancer Research or its publisher, and Journal Metrics does not estimate one because submission counts are not public. What recent PubMed records do show is speed: accepted papers took a median of 78 days from submission to acceptance. To judge selectivity, compare Chinese Journal of Cancer Research's quartile and score with similar journals, or ask the editorial office.
Chinese Journal of Cancer Research's best quartile is Q1. By OpenAlex subfield: Q1 in Pulmonary and Respiratory Medicine; Q1 in Oncology; Q1 in Surgery. Quartiles rank journals by Journal Metrics Score within each subfield.
No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Chinese Journal of Cancer Research will not match this score exactly. Compare journals using one source at a time.
Across 98 recent PubMed records with both dates, Chinese Journal of Cancer Research took a median of 78 days from submission to acceptance; the middle half took 51–105 days. This interval includes editorial handling and revisions, so it is not the time to a first decision.
Comparable journals include Esmo Gastrointestinal Oncology, Cancer Medicine, Clinical Medicine Insights-Oncology, and World Journal of Oncology. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.
Submit online through the link in Chinese Journal of Cancer Research's author guidelines on the journal homepage. Before submitting, check the scope, follow the author guidelines for article type, length, and required statements, and prepare a cover letter. Accepted papers took a median of 78 days from submission to acceptance in recent PubMed records.